Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

In clinical practice natalizumab is typically used in patients who have experienced breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate. In these patients it is important to reduce disease activity as quickly as possible. In a phase II study, differences between natalizumab and placebo in MRI outcomes reflecting inflammatory activity were evident after the first infusion and maintained through a 6-month period, suggesting a rapid onset of natalizumab treatment effects. To explore how soon after natalizumab initiation clinical effects become apparent, annualized relapse rates per 3-month period and time to first relapse were analyzed in the phase III AFFIRM study (natalizumab vs. placebo) and in the multinational Tysabri® Observational Program (TOP). In AFFIRM, natalizumab reduced the annualized relapse rate within 3months of treatment initiation compared with placebo in the overall population (0.30 vs. 0.71; p<0.0001) and in patients with highly active disease (0.30 vs. 0.94; p=0.0039). The low annualized relapse rate was maintained throughout the 2-year study period, and the risk of relapse in AFFIRM patients treated with natalizumab was reduced [hazard ratio against placebo 0.42 (95% CI 0.34-0.52); p<0.0001]. Rapid reductions in annualized relapse rate also occurred in TOP (baseline 1.99 vs. 0-3months 0.26; p<0.0001). Natalizumab resulted in rapid, sustained reductions in disease activity in both AFFIRM and in clinical practice. This decrease in disease activity occurred within the first 3months of treatment even in patients with more active diseas

Ostéonécrose aseptique chez les patients infectés par le VIH (étude de deux cas cliniques au Centre Hospitalier de Valenciennes et revue de la littérature)

LILLE2-BU Santé-Recherche (593502101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Etude descriptive d'une population de co-infectés V.I.H./ V.H.C. au Centre Hospitalier de Valenciennes (42 patients)

LILLE2-BU Santé-Recherche (593502101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Bullous pemphigoid induced by vildagliptin: a report of three cases

International audienceTo report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86-year-old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin. After introduction of clobetasol, the symptoms resolved although vildagliptin was continued. However, the skin lesions reappeared 3 months later. Sustained remission was achieved only after definitive withdrawal of vildagliptin. Case 2: A 79-year-old man presented with bullous pemphigoid after 37-month treatment with gliclazide, vildagliptin and metformin. The disease at first responded to clobetasol but 3 months later the lesions reappeared. They finally regressed when the gliptin was discontinued. Case 3: A 77-year-old woman, treated with gliclazide and vildagliptin for 26 months, presented with bullous pemphigoid, which responded well to discontinuation of the gliptin and topical clobetasol. Gliptins are new molecules for treatment of type 2 diabetes mellitus, which have been suspected of implication in bullous pemphigoid. Such cases have been described in the literature (seven with vildagliptin and three with sitagliptin). In nine of these cases, the gliptin was associated with metformin, but the latter had never been considered responsible. The mechanism implicated in the development of bullous pemphigoid has not yet been clearly identified, but may involve a modified immune response or alteration of the antigenic properties of the epidermal basement membrane. These reports support the risk of bullous pemphigoid in patients exposed to gliptins

Activités du groupe d'Archéologie classique de l'Université de Lille-III en 1972

De La Genière Juliette, Quivron Gonzague, Jelski Georges, Lebrun A., Vermersch A., Martial Christine, Gernez Annick, Desreumaux Isabelle, Bescond Annie, Leblon Marie-Ange, Van Hoeke Nicole, Florin Isabelle, Deblock G., Talleux D., Bouillet M. F., Cellerier M. V. Activités du groupe d'Archéologie classique de l'Université de Lille-III en 1972. In: Revue du Nord, tome 55, n°216, Janvier-mars 1973. pp. 53-59

Activités du groupe d'Archéologie classique de l'Université de Lille-III en 1972

De La Genière Juliette, Quivron Gonzague, Jelski Georges, Lebrun A., Vermersch A., Martial Christine, Gernez Annick, Desreumaux Isabelle, Bescond Annie, Leblon Marie-Ange, Van Hoeke Nicole, Florin Isabelle, Deblock G., Talleux D., Bouillet M. F., Cellerier M. V. Activités du groupe d'Archéologie classique de l'Université de Lille-III en 1972. In: Revue du Nord, tome 55, n°216, Janvier-mars 1973. pp. 53-59

Multi-locus sequence typing of <i>Treponema pallidum</i> subsp. <i>pallidum</i> present in clinical samples from France: Infecting treponemes are genetically diverse and belong to 18 allelic profiles

<div><p><i>Treponema pallidum</i> subsp. <i>pallidum</i>, the causative agent of sexually transmitted syphilis, detected in clinical samples from France, was subjected to molecular typing using the recently developed Multilocus Sequence Typing system. The samples (n = 133) used in this study were collected from 2010–2016 from patients with diagnosed primary or secondary syphilis attending outpatient centers or hospitals in several locations in France. Altogether, 18 different allelic profiles were found among the fully typed samples (n = 112). There were five allelic variants identified for TP0136, 12 for TP0548, and eight for TP0705. Out of the identified alleles, one, seven, and three novel alleles were identified in TP0136, TP0548, and TP0705, respectively. Partial allelic profiles were obtained from 6 samples. The majority of samples (n = 110) belonged to the SS14-like cluster of TPA isolates while 7 clustered with Nichols-like isolates. Patients infected with Nichols-like samples were more often older (<i>p</i> = 0.041) and more often diagnosed with secondary syphilis (<i>p</i> = 0.033) compared to patients infected with SS14-like samples. In addition, macrolide resistance caused by the A2058G mutation was found to be associated with allelic profile 1.3.1 or with strains belonging to the 1.3.1 lineage (<i>p</i><0.001). The genetic diversity among TPA strains infecting the European population was surprisingly high, which suggests that additional studies are needed to reveal the full genetic diversity of TPA pathogens infecting humans.</p></div

MLST allelic profiles of typed samples.

<p>MLST allelic profiles of typed samples.</p

Clinical characteristics of patients with diagnosed syphilis.

<p>Clinical characteristics of patients with diagnosed syphilis.</p